Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 331.45M P/E - EPS this Y -27.30% Ern Qtrly Grth -
Income -47.24M Forward P/E -5.57 EPS next Y -21.40% 50D Avg Chg -12.00%
Sales 850k PEG - EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.89 EPS next 5Y - 52W High Chg -54.00%
Recommedations 1.30 Quick Ratio 15.38 Shares Outstanding 137.59M 52W Low Chg 45.00%
Insider Own 12.04% ROA -20.58% Shares Float 88.57M Beta 0.71
Inst Own 72.08% ROE -30.05% Shares Shorted/Prior 2.30M/1.78M Price 2.62
Gross Margin 100.00% Profit Margin - Avg. Volume 590,404 Target Price 7.57
Oper. Margin -1,770.00% Earnings Date - Volume 286,608 Change -2.24%
About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc. News
11/13/24 Compass Therapeutics to Participate in Upcoming Investor Events
11/12/24 Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
11/08/24 Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/05/24 US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M
10/04/24 Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
08/22/24 Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
08/12/24 Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
08/07/24 Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
08/06/24 Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
07/12/24 Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
05/30/24 Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
05/28/24 Compass Therapeutics Announces CEO Transition
05/23/24 Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
05/14/24 Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
05/13/24 Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
04/25/24 Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
04/16/24 Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
04/12/24 Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
04/10/24 Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
04/09/24 Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
CMPX Chatroom

User Image Malcolm_Hudson Posted - 1 day ago

$CMPX $ATYR $TSVT LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Night_Owl_Biotech Posted - 1 day ago

$STRO is off 40% the last 7 trading days. This is the largest drop of 25 peer clinical-stage oncology focused bios with market caps between $150 & $650MM (see attachment). STRO's enterprise value (market cap - cash) = -$167MM. STRO is running a potential reg'l trial in certain ovarian cancers not suited for Elahere & has engaged a banker (Lazard) to find a long-term partner. Put simplest, it is worth investors efforts to fully research STRO as, though of course STRO could fail, its risk/reward profile is compelling again (especially if you believe stocks like STRO trade in cycles) Other clinical-stage oncology focused bios trading for well less than cash with near-term pot'l value inflection points/data reads incl $CMPX $ITOS & $ZNTL $BDTX trades slightly higher than cash but expects a Phase 2 data read in certain lung cancers in Q125 (BDTX's therapy was deemed "de-risked" by Piper Sandler after an interim read 2 months ago). This is not investment advice.

User Image Kingbibi Posted - 2 days ago

$CMPX we need to go above 1.60

User Image jfdz20 Posted - 3 days ago

$CMPX

User Image proudminer Posted - 6 days ago

$CMPX DOWNGRADE: Compass Therapeutics (CMPX) downgraded by Leerink Partners from Outperform to Market Perform. BRIEFING.COM 7:33 AM ET 11/15/2024 I can't find any specific reasons for the downgrade. Briefing.com requires sign-up. Leerink has brokered offerings for CMPX in the past.

User Image Kingbibi Posted - 6 days ago

$CMPX wow .. they run out of money ? What happened??

User Image IN0V8 Posted - 1 week ago

$CMPX Opportunity Raymond James ups target price to $10 from $8

User Image Stocks4thought Posted - 1 week ago

$CMPX $PRQR $VOR $CRDF FTHA2R- https://www.youtube.com/watch?v=qsaTFcXVCNU

User Image Stocks4thought Posted - 1 week ago

$CMPX Crack cocaine- $CRDF $VOR

User Image Stocks4thought Posted - 1 week ago

$CRDF $CMPX $VOR Dope fest LSD Micro- dosing!!

User Image DARKP00L Posted - 2 weeks ago

$CMPX this stock is attracting a lot of interest. Be prepared for possible changes!

User Image Kingbibi Posted - 2 weeks ago

$CMPX something Is going on …

User Image Fisher_B Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $ENTA $CMPX $ATYR $TSVT

User Image Kingbibi Posted - 2 weeks ago

$CMPX new week let’s see this week how much high can we go let’s break 2

User Image Kingbibi Posted - 2 weeks ago

$CMPX time to fly

User Image Marketwizwallstreet Posted - 1 month ago

$ACET carl gordon @ orbimed sits on relatively few boards. $AVBP $KROS $TERN $CMPX and $ACET orbimed is arguably the best performing bio fund in 2024 Along with ra capital . They own 20% of adicet.

User Image Stocks4thought Posted - 1 month ago

$CMPX mil share pick up at $1.81

User Image jfdz20 Posted - 1 month ago

$CMPX It has not yet touched the 38 fibo of the entire rise so it may fall a little more even

User Image Stocks4thought Posted - 1 month ago

$CMPX New rider- new high coming= https://www.youtube.com/watch?v=Tt6Do5fo4k8

User Image Kingbibi Posted - 1 month ago

$CMPX let’s see this week what will happen

User Image Stocks4thought Posted - 1 month ago

$SGMT Full metal jacket$ ot $CMPX too

User Image Stocks4thought Posted - 1 month ago

$CMPX over $1.88 will set us up to go over $2 again. Catalyst coming and data has been good- reads$

User Image Stocks4thought Posted - 1 month ago

$CMPX The global Bile Duct Cancer Market size is estimated to be valued at USD 3.71 billion in 2024 and is expected to reach USD 6.52 billion in 2031

User Image Jay_Cee_ Posted - 1 month ago

$CMPX following the stock Bought in at 1.6-

User Image Stocks4thought Posted - 09/30/24

$PRME Nobody is smart enough to see $5 been here before= the phony traders. ot $BWay $cmpx #slno $vktx $mrkr

User Image Stocks4thought Posted - 09/30/24

$PRME David Koresh smoking jacket- ot $BWAY $CMPX $MRKR $SLNO we get in before th BS pumpers- fake traders-- wanna be's see old post-

User Image Stocks4thought Posted - 09/30/24

$BWAY $10 Bo Derek................ Simple Simon says- No Kamala-------ot $PRME $CMPX $SLNO

User Image Stocks4thought Posted - 09/30/24

$BWAY We tried to tell you awhile ago ot $PRME we tried to tell you the same thing. Next $CMPX

User Image Kingbibi Posted - 09/29/24

$CMPX can we break 2 this week ???

User Image Stocks4thought Posted - 09/26/24

$CMPX California Dreaming- no- I mean its gonna blow past $2............cali is done - Thanks to the liberals! Read out Q1 and possible marketing approval following year?

Analyst Ratings
Ladenburg Thalmann Buy Sep 16, 24
HC Wainwright & Co. Buy Aug 12, 24
Wedbush Outperform Aug 7, 24
HC Wainwright & Co. Buy Aug 6, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy May 14, 24
HC Wainwright & Co. Buy Apr 16, 24
Wedbush Outperform Mar 22, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Mar 10 Buy 3.37 10,000 33,700 6,021,873 03/10/23
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 27 Buy 3.98 20,000 79,600 6,011,873 02/27/23
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 15 Buy 3.86 20,000 77,200 5,991,873 02/15/23
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 31 Buy 4.05 20,000 81,000 5,471,873 01/31/23
Bisker-Leib Vered Chief Operating Offi.. Chief Operating Officer Nov 22 Sell 4.28 24,500 104,860 1,060,414 11/25/22
ORBIMED ADVISORS LLC Director Director Nov 08 Buy 3.21 402,000 1,290,420 15,219,994 11/10/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 28 Buy 2.32 10,000 23,200 5,431,873 09/28/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 26 Buy 2.27 15,000 34,050 5,421,873 09/27/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 07 Buy 3.03 15,000 45,450 5,406,873 09/08/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 01 Buy 2.83 15,000 42,450 5,391,873 09/01/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 10 Buy 2.64 15,000 39,600 5,361,873 08/10/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 01 Buy 2.58 15,000 38,700 5,346,873 08/02/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 21 Buy 2.80 20,000 56,000 5,331,873 06/21/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 06 Buy 2.83 30,000 84,900 5,261,873 06/07/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 01 Buy 3.03 20,000 60,600 5,231,873 06/01/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 26 Buy 3.04 20,000 60,800 5,211,873 05/26/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 23 Buy 2.72 18,355 49,926 5,191,873 05/24/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 17 Buy 2.47 20,215 49,931 5,173,518 05/17/22
GORDON CARL L Director Director May 11 Buy 2.21 192,516 425,460 14,817,994 05/13/22
ORBIMED ADVISORS LLC Director Director May 11 Buy 2.21 192,516 425,460 14,817,994 05/13/22
ORBIMED ADVISORS LLC Director Director May 06 Buy 1.6 125,359 200,574 14,625,478 05/10/22
GORDON CARL L Director Director May 06 Buy 1.6 125,359 200,574 14,625,478 05/10/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 10 Buy 1.80 27,836 50,105 5,153,303 05/10/22
GORDON CARL L Director Director Nov 04 Buy 3.5 5,357,143 18,750,000 3,571,428 11/08/21
ORBIMED ADVISORS LLC Director Director Nov 04 Buy 3.5 5,357,143 18,750,000 3,571,428 11/08/21